Filing Details
- Accession Number:
- 0001144204-14-001504
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-09 21:30:16
- Reporting Period:
- 2014-01-07
- Filing Date:
- 2014-01-09
- Accepted Time:
- 2014-01-09 21:30:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1270073 | Intercept Pharmaceuticals Inc | ICPT | Pharmaceutical Preparations (2834) | 223868459 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1276039 | Lorenzo Tallarigo | C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2014-01-07 | 1,839 | $67.41 | 1,640 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 5,938,890 | Indirect | See Footnote |
Footnotes
- The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 18, 2013.
- Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
Billionaire Hedge Funds
